Improved cardiovascular function with aminoguanidine in DOCA-salt hypertensive rats

British Journal of Pharmacology

Volumn 148, Issue 7, 2006, Pages 902-908

  Chan, Vincent ^a   Hoey, Andrew ^b   Brown, Lindsay ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF SOUTHERN QUEENSLAND   (Australia)

Author keywords

Aminoguanidine; Collagen crosslinking; DOCA salt rats; Hypertension; Remodelling

Indexed keywords

ACETYLCHOLINE; AMINOGUANIDINE; DEOXYCORTICOSTERONE ACETATE; NITROPRUSSIDE SODIUM; TILETAMINE; XYLAZINE; ZOLAZEPAM; ZOLETIL; COLLAGEN; CROSS LINKING REAGENT; DEOXYCORTICOSTERONE; GUANIDINE DERIVATIVE;

ACTION POTENTIAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL REACTIVITY; CARDIOVASCULAR FUNCTION; CELL INFILTRATION; CONTROLLED STUDY; CROSS LINKING; DIASTOLE; HEART LEFT VENTRICLE WALL; HEART MUSCLE CONTRACTILITY; HEART REPOLARIZATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HISTOPATHOLOGY; HYPERTENSION; INFLAMMATORY CELL; ISOLATED HEART; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTOLIC HYPERTENSION; THORACIC AORTA; VASCULARIZATION; ANIMAL; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; ECHOGRAPHY; HEART DISEASE; HEART LEFT VENTRICLE FUNCTION; IN VITRO STUDY; METABOLISM; MICROELECTRODE; NEPHRECTOMY; NEUTROPHIL CHEMOTAXIS; PATHOLOGY; PATHOPHYSIOLOGY; VASCULAR ENDOTHELIUM; WISTAR RAT;

ACTION POTENTIALS; ANIMALS; AORTA, THORACIC; CARDIOVASCULAR DISEASES; COLLAGEN; CROSS-LINKING REAGENTS; DESOXYCORTICOSTERONE; ENDOTHELIUM, VASCULAR; GUANIDINES; HEART DISEASES; HYPERTENSION; MALE; MICROELECTRODES; NEPHRECTOMY; NEUTROPHIL INFILTRATION; RATS; RATS, WISTAR; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 33749326981     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706801     Document Type: Article

References (48)

1. ABDEL-RAHMAN, E. & BOLTON, W.K. (2002). Pimagedine: a novel therapy for diabetic nephropathy. Exp. Opin. Invest. Drugs, 11, 565-574.
2. ALLAN, A., FENNING, A., LEVICK, S., HOEY, A. & BROWN, L. (2005). Reversal of cardiac dysfunction by selective ET-A receptor antagonism. Br. J. Pharmacol., 146, 846-853.
3. AMMARGUELLAT, F.Z., GANNON, P.O., AMIRI, F. & SCHIFFRIN, E.L. (2002). Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ETA receptors. Hypertension, 39, 679-684.
4. BADENHORST, D., MASEKO, M., TSOTETSI, O.J., NAIDOO, A., BROOKSBANK, R., NORTON, G.R. & WOODIWISS, A.J. (2003). Cross-linking influences the impact of quantitative changes in myocardial collagen on cardiac stiffness and remodelling in hypertension in rats. Cardiovasc. Res., 57, 632-641.
5. BAKRIS, G.L., BANK, A.J., KASS, D.A., NEUTEWL, J.M., PRESTON, R.A. & OPARIL, S. (2004). Advanced glycation end-product cross-link breakers. A novel approach to cardiovascular pathologies related to the aging process. Am. J. Hypertens., 17, 23S-30S.
6. 2+ exchange. Naunyn-Schmiedeberg's Arch. Pharmacol., 344, 220-224.
7. BROWN, L., DUCE, B., MIRIC, G. & SERNIA, C. (1999). Reversal of cardiac fibrosis in deoxycorticosterone acetate-salt hypertensive rats by inhibition of the renin-angiotensin system. J. Am. Soc. Nephrol., 10, S143-S148.
8. BROWN, L., FENNING, A., CHAN, V., LOCH, D., WILSON, K., ANDERSON, B. & BURSTOW, D. (2002). Echocardiographic assessment of cardiac structure and function in rats. Heart Lung Circ., 11, 167-173.
9. BROWNLEE, M. (1995). Advanced protein glycosylation in diabetes and aging. Annu. Rev. Med., 46, 223-234.
10. BROWNLEE, M., VLASSARA, H., KOONEY, A., ULRICH, P. & CERAMI, A. (1986). Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking. Science, 232, 1629-1632.
11. BUCALA, R., TRACEY, K.J. & CERAMI, A. (1991). Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes. J. Clin. Invest., 97, 432-438.
12. CANTINI, C., KIEFFER, P., CORMAN, B., LIMIÑANA, P., ATKINSON, J. & LARTAUD-IDJOUADIENE, I. (2001). Aminoguanidine and aortic wall mechanics, structure, and composition in aged rats. Hypertension, 38, 943-948.
13. CORMAN, B., DURIEZ, M., POITEVIN, P., HEUDES, D., BRUNEVAL, P., TEDGUI, A. & LEVY, B.I. (1998). Aminoguanidine prevents agerelated arterial stiffening and cardiac hypertrophy. Proc. Natl. Acad. Sci. U.S.A., 95, 1301-1306.
14. EDELSTEIN, D. & BROWNLEE, M. (1992). Mechanistic studies of advanced glycosylation end product inhibition by aminoguanidine. Diabetes, 41, 26-29.
15. FENNING, A., HARRISON, G., ROSE'MEYER, R., HOEY, A. & BROWN, L. (2005). L-Arginine attenuates cardiovascular impairment in DOCA-salt hypertensive rats. Am. J. Physiol., 289, H1408-H1416.
16. FUJISAWA, G., DILLEY, R., FULLERTON, M.J. & FUNDER, J.W. (2001). Experimental cardiac fibrosis: differential time course of response to mineralocorticoid-salt administration. Endocrinology, 142, 3625-3631.
17. GIARDINO, I., FARD, A.K., HATCHELL, D.L. & BROWNLEE, M. (1998). Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation and oxidant induced apoptosis. Diabetes, 47, 1114-1120.
18. GRIFFITHS, M.J.D., MESSENT, M., MACALLISTER, R.J. & EVANS, T.W. (1993). Aminoguanidine selectively inhibits inducible nitric oxide synthase. Br. J. Pharmacol., 110, 963-968.
19. HART, G. (1994). Cellular electrophysiology in cardiac hypertrophy and failure. Cardiovasc. Res., 28, 933-946.
20. HONG, H., LOH, S. & YEN, M. (2000). Suppression of the development of hypertension by the inhibitor of inducible nitric oxide synthase. Br. J. Pharmacol., 131, 631-637.
21. KIRCHNER, K.A., SCANLON JR, P.H., DZIELAK, D.J. & HESTER, R.L. (1993). Endothelium-derived relaxing factor responses in DOCA-salt hypertensive rats. Am. J. Physiol., 265, R568-R572.
22. KOCHAKIAN, M., MANJULA, B.N. & EGAN, J.J. (1996). Chronic dosing with aminoguanidine and novel glycosylation end product-formation inhibitors ameliorates cross-linking of tail tendon collagen in STZ-induced diabetic rats. Diabetes, 45, 1694-1700.
23. KOJDA, G. & HARRISON, D. (1999). Interactions between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc. Res., 43, 562-571.
24. LAKATTA, E.G. (1993). Cardiovascular regulatory mechanisms in advanced age. Physiol. Rev., 73, 413-467.
25. LANDER, H.M., TAURAS, J.M., OGISTE, J.S., HORI, O., MOSS, R.A. & SCHMIDT, A.M. (1997). Activation for the receptor for AGE triggers a p21 ras dependent mitogen activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem., 272, 17810-17814.
26. LI, Y., STEFFES, M., DONNELLY, T., LIU, C., FUH, H., BASGEN, J., BUCALA, R. & VLASSARA, H. (1996). Prevention of cardiovascular and renal pathology of aging by the advanced glycation inhibitor aminoguandine. Proc. Natl. Acad. Sci. U.S.A., 93, 3902-3907.
27. LITTLE, W.C., ZILE, M.R., KITZMAN, D.W., HUNDLEY, W.G., O'BRIEN, T.X. & DEGROOF, R.C (2005). The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J. Card. Fail., 11, 191-195.
28. MIYAUCHI, Y., SHILAMA, H., TAKASU, T., OKAMIYA, H., UMEDA, M., HIRASAKI, E., OHHATA, I., NAKAYAMA, H. & NAKAGAWA, S. (1996). Slowing of peripheral nerve conduction was ameliorated by aminoguanidine in streptozotocin-induced diabetic rats. Eur. J. Endocrinol., 134, 467-473.
29. MIZUTANI, K., IKEDA, K., TSUDA, K. & YAMORI, Y. (2002). Inhibitor for advanced glycation end products formation attenuates hypertension and oxidative damage in genetic hypertensive rats. J. Hypertens., 20, 1607-1614.
30. MOMTAZ, A., COULOMBE, A., RICHER, P., MERCADIER, J.-J. & CORABOEUF, E. (1996). Action potential and plateau ionic currents in moderately and severely DOCA-salt hypertrophied rat hearts. J. Mol. Cell Cardiol., 28, 2511-2522.
31. NILSSON, B. (1999). Biological effects of aminoguanidine: an update. Inflamm. Res., 48, 509-515.
32. NORTON, G.R., CANDY, G. & WOODIWISS, A.J. (1996). Aminoguanidine prevents the decreased myocardial compliance produced by streptozotocin-induced diabetes mellitus in rats. Circulation, 93, 1905-1912.
33. NORTON, G.R., TSOTETSI, J., TRIFUNOVIC, B., HARTFORD, C., CANDY, G.P. & WOODIWISS, A.J. (1997). Myocardial stiffness is attributed to alterations in cross-linked collagen rather than total collagen or phenotypes in spontaneously hypertensive rats. Circulation, 96, 1991-1998.
34. OOSHIMA, A. & MIDORIKAWA, O. (1977). Increased lysyl oxidase activity in blood vessels of hypertensive rats and effect of β-aminopropionitrile on arteriosclerosis. Jpn. Circ. J., 41, 1337-1340.
35. OYAMA, J., SHIMOKAWA, H., MOMII, H., CHENG, X., FUKUYAMA, N., ARAI, Y., EGASHIRA, K., NAKAZAWA, H. & TAKESHITA, A. (1998). Role of nitric oxide and peroxynitrite in the cytokineinduced sustained myocardial dysfunction in dogs in vivo. J. Clin. Invest., 101, 2207-2214.
36. PANAGIOTOPOULOS, S., O'BRIEN, R.C., BUCCALA, R., COOPER, M.E. & JERUMS, G. (1998). Aminoguanidine has an antiatherogenic effect in the cholesterol-fed rabbit. Atherosclerosis, 136, 125-131.
37. RECKELHOFF, J.F., HENNINGTON, B.S., KANJI, V., RACUSEN, L.C., SCHMIDT, A.M., YAN, S.D., MORROW, J., ROBERTS II, L.J. & SALAHUDEEN, A.K. (1999). Chronic aminoguanidine attenuates renal dysfunction and injury in aging rats. Am. J. Hypertens., 12, 492-498.
38. REDFIELD, M.M. (2005). Treating diastolic heart failure with AGE crosslink breakers: thinking outside the heart failure box. J. Card. Fail, 11, 196-199.
39. SALVEMINI, D., MANNING, P.T., ZWEIFEL, B.S., SEIBERT, K., CONNOR, J., CURRIE, M.G., NEEDLEMAN, P. & MASFERRER, J.L. (1995). Dual inhibition of nitric oxide and prostaglandin production contributes to the antiinflammatory properties of nitric oxide synthase inhibitors. J. Clin. Invest., 96, 301-308.
40. SOMERS, M.J., MAVROMATIS, K., GALIS, Z.S. & HARRISON, D.G. (2000). Vascular superoxide production and vasomotor function in hypertension induced by deoxycorticosterone acetate-salt. Circulation, 101, 1722-1728.
41. SUN, Y., ZHANG, J., LU, L., BEDIGIAN, M.P., ROBINSON, A.D. & WEBER, K.T. (2004). Tissue angiotensin II in the regulation of inflammatory fibrogenic components of repair in the rat heart. J. Lab. Clin. Med., 143, 41-51.
42. SWAMY-MRUTHINTI, S., GREEN, K. & ABRAHAM, E.C. (1996). Inhibition of cataracts in moderately diabetic rats by aminoguanidine. Exp. Eye Res., 62, 505-510.
43. VASAN, S., FOILES, P. & FOUNDS, H. (2003). Therapeutic potential of breakers of advanced glycation end-product-protein cross-linkages. Arch. Biochem. Biophys., 419, 89-96.
44. WEBER, K.T., BRILLA, C.G. & JANICKI, J.S. (1993). Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc. Res., 27, 341-348.
45. WU, L. & JUURLINK, B.H.J. (2002). Increased methylglyoxal and oxidative stress in hypertensive rat vascular smooth muscle cells. Hypertension, 39, 809-814.
46. WU, R., MILLETTE, E., WU, L. & DE CHAMPLAIN, J. (2001). Enhanced superoxide anion formation in vascular tissues from spontaneously hypertensive and desoxycorticosterone acetate-salt hypertensive rats. J. Hypertens., 19, 741-748.
47. YAN, S.D., SCHIMDT, A.M. & ANDERSON, G.M. (1994). Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J. Biol. Chem., 269, 9889-9897.
48. ZIOLO, M.T., HARSHBARGER, C.H., ROYCROFT, K.E., SMITH, J.M., ROMANO, F.D., SONDGEROTH, K.L. & WAHLER, G.M. (2001). Myocytes isolated from rejecting transplanted rat hearts exhibit a nitric oxide-mediated reduction in the calcium current. J. Mol. Cell Cardiol., 33, 1691-1699.